Biological
Human Papillomavirus Recombinant Vaccine nonavalent clinical trials
- studies test it
- 63
- open now
- 20
- in phase 3
- 19
- first study started
- 2012
Keep track of what changes. Save the Human Papillomavirus Recombinant Vaccine nonavalent studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
63 studies that test it; most in 2022 (10)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 7 |
| 2021 | 6 |
| 2022 | 10 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 7 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 14
- Phase 3
- 19
- Phase 4
- 28
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 51
Merck Sharp & Dohme LLC (9) · National Cancer Institute (NCI) (5) · London School of Hygiene and Tropical Medicine (2) · Boston Medical Center (2) · Indiana University (2) · Emory University (2) · Fred Hutchinson Cancer Center (2) · Shanghai Bovax Biotechnology Co., Ltd. (2)
Often tested with
Tested in the same studies.
Human papillomavirus vaccine, L1 type 16, 18 (4) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (2) · Meningococcal Vaccines (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Lidocaine (1) · 2019-nCoV Vaccine mRNA-1273 (1) · Papillomavirus Vaccines (1) · Imiquimod (1)
Studies
Open first, then newest update. How each study uses Human Papillomavirus Recombinant Vaccine nonavalent is read from its arms, and is right about nine times in ten.
Testing it · 63
- Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*Not yet recruitingPhase 1/2Ohio State UniversityNCT07339163Written as GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
- ESCUDDO Long Term Follow UpEnrolling by invitationPhase 4National Cancer Institute (NCI)NCT07706673Written as Recombinant Human Papillomavirus Nonavalent Vaccine
- Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSILRecruitingPhase 4Erasmus Medical CenterNCT06052696Written as Gardasil 9 Suspension for Injection
- HPV Vaccine Reduced DoseRecruitingPhase 4Emory UniversityNCT06799494Written as Gardasil-9
- Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIVRecruitingPhase 2University of Maryland, BaltimoreNCT06624839Written as Human papillomavirus (HPV) vaccine, 9-valent
- Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV VaccinationRecruitingPhase 2Universiteit AntwerpenNCT07407569Written as Gardasil 9 (2 dose regimen)
- Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical LesionsRecruitingPhase 2Centre Oscar LambretNCT06658405Written as Human Papillomavirus 9-valent Vaccine, Recombinant
- Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPVNot yet recruitingPhase 2Institut d'Investigació Biomèdica de BellvitgeNCT07303751Written as Nonavalent HPV vaccine (9vHPV)
- A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIVRecruitingPhase 4University of British ColumbiaNCT05495906Written as Nonavalent HPV vaccine
- The Mother-Daughter Project: Merck-4Not yet recruitingNot applicableIndiana UniversityNCT07240220Written as Gardisil-9
- Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female StudentsRecruitingPhase 4Canadian Immunization Research NetworkNCT07156084Written as HPV nonavalent vaccine (Gardasil-9)
- Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIVRecruitingPhase 4Louisiana State University Health Sciences Center in New OrleansNCT05266898Written as Human papillomavirus 9-valent vaccine, recombinant
- Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus ExposureNot yet recruitingPhase 2National Institute of Hygiene and Epidemiology, VietnamNCT06681636Written as Human papillomavirus 9-valent vaccine, Recombinant
- Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in RwandaNot yet recruitingPhase 4Rwanda Biomedical CentreNCT06536855Written as Gardasil 9
- Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 YearsRecruitingPhase 3Shanghai Bovax Biotechnology Co., Ltd.NCT04895020Written as 9-valent HPV vaccine
- Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous WartsRecruitingPhase 2/3Western Institute for Veterans ResearchNCT05625633Written as Human Papillomavirus 9-valent Vaccine, Recombinant
- Immunogenicity of 9-valent HPV VaccineRecruitingPhase 4Talia Sainz CostaNCT05439083Written as 9-valent HPV vaccine
- HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSILNot yet recruitingPhase 2University Health Network, TorontoNCT03947775Written as 9-valent HPV vaccination
- Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in SwedenRecruitingPhase 4Miriam ElfströmNCT04910802Written as Gardasil9
- Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9Not yet recruitingPhase 3Alessandro GhelardiNCT03848039Written as Gardasil-9
See all 63 studies that test Human Papillomavirus Recombinant Vaccine nonavalent →
Given in every arm · 4 — Human Papillomavirus Recombinant Vaccine nonavalent is usual care beside what is tested
- Testing RG1-VLP Vaccine to Prevent HPV-related CancersRecruitingPhase 1National Cancer Institute (NCI)NCT05985681Written as Recombinant Human Papillomavirus Nonavalent Vaccine
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy AdolescentsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT04490018Written as Human Papillomavirus 9-valent Vaccine (9vHPV)
- Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 YearsCompletedPhase 3TakedaNCT04313244Written as 9vHPV Vaccine
- A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 YearsStatus unknownPhase 1Sinocelltech Ltd.NCT04921111Written as Gardasil®9
As the comparator · 10 — what is tested is compared with Human Papillomavirus Recombinant Vaccine nonavalent
- Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) VaccineNot yet recruitingPhase 1/2Serum Institute of India Pvt. Ltd.NCT07888686Written as Gardasil9
- Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).RecruitingPhase 1Merck Sharp & Dohme LLCNCT06623409Written as GARDASIL®9 (G9)
- A Clinical Study of V540A in Healthy Female Participants (V540A-005)WithdrawnPhase 2Merck Sharp & Dohme LLCNCT07224477Written as GARDASIL®9
- A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)Active, not recruitingPhase 1Merck Sharp & Dohme LLCNCT06688058Written as GARDASIL®9
- A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of AgeCompletedPhase 1/2GlaxoSmithKlineNCT05496231Written as Gardasil 9
- A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) VaccineActive, not recruitingPhase 3Beijing Health Guard Biotechnology, IncNCT06207175Written as GARDASIL® 9
- Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCompletedPhase 3Shanghai Bovax Biotechnology Co., Ltd.NCT05372016Written as Active Comparator: GARDASIL ®9
- Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of AgeCompletedPhase 3Xiamen UniversityNCT04782895Written as Gardasil®9
- A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in ChinaActive, not recruitingPhase 3Beijing Health Guard Biotechnology, IncNCT05662020Written as GARDASIL® 9
- Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9Status unknownPhase 3Shanghai Zerun Biotechnology Co.,LtdNCT05580341Written as GARDASIL ®9